Hansoh Pharma's Innovation Power Is Unmistakable: Revenue from Innovative Drugs Soars to 82% in 2025

The proportion of innovative business revenue of Hansoh Pharma has increased from less than 20% in 2020,Increased to 82% by 2025This remarkable achievement is not only due to the continued growth of products such as Aumetinib, Flumatinib, and Inebilizumab, but also the consecutive breakthroughs in the company's BD collaborations.

Insight database shows that Hansoh Pharma has reached 7 deals so far, of whichAll 5 deals were reached with leading global MNCs, involving 4 companies, each with a total amount exceeding 1.5 billion US dollars.From a technical perspective, it covers the currently hottest ADC and GLP-1 products.

Notably, inAmong China's leading pharmaceutical companies, Hansoh is one of the companies with the most partnerships with multinational corporations (MNCs). In the global innovative drug landscape, a single collaboration with a pharmaceutical giant might be considered a stroke of luck, but multiple collaborations, especially being successively chosen by different multinational pharmaceutical enterprises, strongly demonstrate the company's innovative capabilities.

In today's video, we willFrom the perspectives of both sellers and buyers, break down why pharmaceutical giants particularly favor Hansoh.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent Moon

PR Article Coordination: WeChat insightxb